What AI says about Roivant Sciences

Roivant Sciences reinvents the discovery, development, and commercialization of new medicines by building agile, focused companies called Vants. The company leverages technology across discovery, development, and commercialization to advance a broad pipeline of investigational drugs, including FDA-approved therapies such as LISRAYA (brepocitinib) for adults with dermatomyositis. Its model aligns incentives across its Vants to drive fast, high-quality execution and disciplined capital allocation.